Ignite Creation Date:
2024-05-06 @ 8:07 PM
Last Modification Date:
2024-10-26 @ 3:21 PM
Study NCT ID:
NCT06269133
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-03-13
First Post:
2024-02-13
Brief Title:
Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line 1L Treatment of Advanced Non-Small Cell Lung Cancer NSCLC in Adult United States US Patients
Sponsor:
Regeneron Pharmaceuticals
Organization:
Regeneron Pharmaceuticals
Organization Data
Organization:
Regeneron Pharmaceuticals
Class:
INDUSTRY
Study ID:
R2810-ONC-22115
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Regeneron Pharmaceuticals
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None